1. Adly C, Straumanis J, Chesson A. Fluoxetine prophyaxis of migraine. Headache 1992;2:101-4.

2. Anonymous : Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Arch Gen Psychiatry 1992;49:139-147.

3. Aubineau P, Cunin G, Brochet B, Louvet-Giendaj C, Henry P. Release of serotonin only in painful area during cluster headache attacks. The Lancet 1992;339:1294-5.

4. Barr LC, Goodman WK, McDougle CJ, Delgado PL, Heninger GR, Charney DS, Price LH: Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:309-317.

5. Barr LC, Heninger GR, Goodman W, Charney DS, Price LH: Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry 1997;41:949-954.

6. Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M. Treatment of ADHD with fluoxetine: a preliminary trial. J Amer Acad of Child & Adolescent Psychiat 1991;30:762-767.

7. Bateman DN. Sumatriptan. Lancet 1993;341:221-224.

8. Bennett R: Fibromyalgia, chronic fatigue syndrome, and myofascial pain. [Review] [81 refs]. Curr Opin Rheumatol 1998;10:95-103.

9. Bolte MA, Avery D. Case of fluoxetine-induced remission of Raynaud's phenomenon - a case report. Angiology 1993;2:161-3.

10. Cappiello A, Sernyak MJ, Malison RT, McDougle CJ, Heninger GR, Price LH: Effects of acute tryptophan depletion in lithium-remitted manic patients: a pilot study. Biol Psychiatry 1997;42:1076-1078.

11. Cassidy F, Murry E, Carroll BJ: Tryptophan depletion in recently manic patients treated with lithium. Biol Psychiatry 1998;43:230-232.

12. Cassidy F, Murry E, Weiner RD, Carroll BJ: Lack of relapse with tryptophan depletion following successful treatment with ECT. Am J Psychiatry 1997;154:1151-1152.

13. Coccaro EF, Kavoussi RJ: Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997;54:1081-1088.

14. Cook EM, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Amer Acad of Child & Adolescent Psychiat 1992;31:7390745.

15. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Black A, Perel JM, Thase ME: Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacol Bull 1997;33:165-170.

16. Curran HV, Travill RA: Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. Addiction 1997;92:821-831.

17. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L: Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 1996;4:391-396.

18. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiat 1990;47:411-418.

19. Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ, Charney DS: Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29:389-396.

20. Delgado PL, Miller HM, Salomon RM, Licinio J, Krystal JH, Heninger, GR, Charney, DS. Tryptophan depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action. (in press)

21. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, Charney DS: Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 1994;51:865-874.

22. Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal JH, Heninger GR, Charney DS: Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol Bull 1991;27:321-330.

23. Diegoli MS, da Fonseca AM, Diegoli CA, Pinotti JA: A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet 1998;62:63-67.

24. Downing J: The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986;18:335-340.

25. Eisendrath SJ, Kodama KT. Fluoxetine management of chronic abdominal pain. Psychosomatics 1992;2:L227-9.

26. Ellenbogen MA, Young SN, Dean P, Palmour RM, Benkelfat C: Mood response to acute tryptophan depletion in healthy volunteers: sex differences and temporal stability. Neuropsychopharmacology 1996;15:465-474.

27. Fatemi SH, Realmuto GM, Khan L, Thuras P: Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998;28:303-307.

28. Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiat 1992;49:139-147.

29. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C: A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-1859.

30. Goldman MB, Janecek HM. Adjunctive fluoxetine improves global function in chronic schizophrenia. J Neuropsychiat & Clin Neurosci 1990;4:429-431.

31. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psych 1990;47:577-585.

32. Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcoholism 1992;16:261-265.

33. Gross MD. Treatment of pathological jealousy by fluoxetine (letter). Amer J Psychiat 1991;148:683-684.

34. Grubb BP, Wolfe DA, Samoil D, Temesy-Armos P, Hahn H, Elliott L. Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope. Pacing & Clinical Electrophysiol 1993;3:458-64.

35. Gruber AJ, Hudson JI, Pope HG,Jr.: The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder. [Review] [79 refs]. Psychiatr Clin North Am 1996;19:351-369.

36. Haensel SM, Klem TM, Hop WC, Slob AK: Fluoxetine and premature ejaculation: a double-blind, crossover, placebo-controlled study. J Clin Psychopharmacol 1998;18:72-77.

37. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen T, Domernowsky P. Ondansetron plus metopimazine compared with ondanetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993;328:1076-1080.

38. Hollander E, Liebowitz MR, DeCaria C, Fairbanks J, Fallon B, Klein DF. Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol 1990;10:200-203.

39. Kafka MP, Prentky P. Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiat 1992;10:351-8.

40. Kenny GN, Oates JL, Leeser J. et al. Efficacy of orally administered ondansetron in the prevention of postoperative nausea and vomiting: a dose ranging study. Brit J Anaesthesia 1992;68:466-470.

41. Koran LM, Raghavan S. Fluoxetine for isolated sleep paralysis. Psychosomatics 1993;.2:184-7.

42. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR: Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 1992;18:331-341.

43. Kurlan R, Como PG, Deeley C, McDermott M, McDermott MP. A pilot controlled study of fluoxetine for obsessive compulsive symptoms in children with Tourette's syndrome. Clin Neuropharmacol 1993;16:167-172.

44. Lam RW, Zis AP, Grewal A, Delgado PL, Charney DS, Krystal JH: Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy. Arch Gen Psychiatry 1996;53:41-44.

45. Leonard HL, Lenane MC, Swedo SE, Retew DC, Rapoport JL. A double-blind comparison of clomipraimine and desipramine treatment of severe onychophagia (nail biting). Arch Gen Psychiat 1991;48(9):821-7.

46. Levitt M, Warr D, Yelle L, et al. Ondansetron compared with dexamethasone and metoclopramide as antimetics in the chemotherapy of breast cancer with cyclophosphamide methotrexate, and fluorouracil. N Engl J Med 1993;328:1081-4.

47. Leyton M, Young SN, Blier P, Ellenbogen MA, Palmour RM, Ghadirian AM, Benkelfat C: The effect of tryptophan depletion on mood in medication-free, former patients with major affective disorder. Neuropsychopharmacology 1997;16:294-297.

48. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry 1998;44:151-162.

49. Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL: Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 1997;21:97-102.

50. Mamounas L, Mullen CA, O'Hearn E, Molliver ME. Dual serotonergic projects to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Compar Neurol 1991;314:558-586.

51. Markowitz PI. Effect of fluoxetine on self-injurious behavior in the developmentally disabled: a preliminary study. J Clin Psychopharmacol 1992;12:27-31.

52. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;19:1250-6.

53. McCann UD, Ricaurte GA: Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence. J Clin Psychopharmacol 1993;13:214-217.

54. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA: Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998;352:1433-1437.

55. Moore P, Gillin C, Bhatti T, DeModena A, Seifritz E, Clark C, Stahl S, Rapaport M, Kelsoe J: Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry 1998;55:534-539.

56. Morgan MJ: Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 1998;19:252-264.

57. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med 1993;44:145-54.

58. Nagy LM, Morgan CA, Southwick SM, Charney DS. Open prospective trial of fluoxetine for post-traumatic stress disorder. J Clin Psychopharmacol 1993;13:107-113.

59. Nelson JC: Synergistic benefits of serotonin and noradrenaline reuptake inhibition. Depress Anxiety 1998;7 Suppl 1:5-6.

60. Nestler EJ. Antidepressant treatment in the 21st century. Biol Psychiatry 1998;44:526-533.

61. Neumeister A, Praschak-Rieder N, Besselmann B, Rao ML, Gluck J, Kasper S: Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during a stable response to bright light therapy. Arch Gen Psychiatry 1997;54:133-138.

62. Neumeister A, Praschak-Rieder N, Hesselmann B, Vitouch O, Rauh M, Barocka A, Kasper S: Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer [see comments]. Psychol Med 1998;28:257-264.

63. Neumeister A, Praschak-Rieder N, Hesselmann B, Vitouch O, Rauh M, Barocka A, Kasper S: Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. Am J Psychiatry 1997;154:1153-1155.

64. Neumeister A, Praschak-Rieder N, Hesselmann B, Vitouch O, Rauh M, Barocka A, Tauscher J, Kasper S: Effects of tryptophan depletion in drug-free depressed patients who responded to total sleep deprivation. Arch Gen Psychiatry 1998;55:167-172.

65. Neumeister A, Turner EH, Matthews JR, Postolache TT, Barnett RL, Rauh M, Vetticad RG, Kasper S, Rosenthal NE: Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry 1998;55:524-530.

66. Oldman A, Walsh A, Salkovskis P, Fairburn CG, Cowen PJ: Biochemical and behavioural effects of acute tryptophan depletion in abstinent bulimic subjects: a pilot study. Psychol Med 1995;25:995-1001.

67. Panzer MJ, Mellow AM. Antidepressant treatment of pathologic laughing or crying in elderly stroke patients. J Geriatric Psychiat & Neurol 1992; 4:195-199.

68. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K: Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits. J Psychopharmacol 1998;12:79-83.

69. Petitto JM, Mundle LB, Nagy BR, Evans DL, Golden RN. Improvement of arthritis with fluoxetine. Psychosomatics 1992;3:338-41.

70. Phillips KA, McElroy SL, Keck PE, Pope HG, Hudson JI. Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiat 1993;150:302-308.

71. Platt AJ, Heddle RM, Rake MO, Smedley H. Ondansetron in carcinoid syndrome. The Lancet 1992;339:1416.

72. Pomerleau OF, Pomerleau CS, Morrell EM, Lowenberg JM. Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake. Psychoneuroendocrinology 1991;16:433-440.

73. Reilly JG, McTavish SF, Young AH: Rapid depletion of plasma tryptophan: a review of studies and experimental methodology. [Review] [85 refs]. J Psychopharmacol 1997;11:381-392.

74. Ricaurte GA, Finnegan KT, Irwin I, Langston JW. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. In: Whitaker PM, Peroutka SJ, eds. The neuropharmacology of serotonin, New York:Annals of the NY Academy of Sciences, 1990;600:699.

75. Salomon RM, Miller HL, Krystal JH, Heninger GR, Charney DS: Lack of behavioral effects of monoamine depletion in healthy subjects. Biol Psychiatry 1997;41:58-64.

76. Shopsin B, Friedman E, Gershon S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976;33:811-819.

77. Sichel DA, Cohen LS, Dimmock JA, Rosenbaum JF. Postpartum obsessive compulsive disorder: a case series. J Clin Psychiat 1993;54:156-159.

78. Sjoerdsma A, Palfreyman MG. History of serotonin and serotonin disorders. In: Whitaker-Azmitia PM, Peroutka SJ, eds. The neuropharmacology of serotonin, New York:Annals of the NY Academy of Sciences, 1990;600:1-8.

79. Smeraldi E, Diaferia G, Erzegovesi S, Lucca A, Bellodi L, Moja EA. Tryptophan depletion in obsessive -compulsive patients. Biol Psychiatry 1996;40:398-402.

80. Smith KA, Fairburn CG, Cowen PJ. Symptomatic relapse in bulimia nervosa following acute tryptophan depletion. Arch Gen Psychiatry 1999;56:171-176.

81. Smith KA, Fairburn CG, Cowen PJ: Relapse of depression after rapid depletion of tryptophan [see comments]. Lancet 1997;349:915-919.

82. Swedo SE, Leonard HL, Rapoport JL, Lenane MC, Goldberger EL, Cheslow DL. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). New Engl J Med 1989;321(8):497-501.

83. Takeda N, Morita M, Hasegawa S, Horii A, Kubo T, Matsunaga T. Neuropharmacology of Motion Sickness and Emesis. Acta Otolaryngol (Stockh) 1993;501:10-15.

84. Tansey M, Pilgrim A, Lloyd K. Sumatriptan in the acute treatment of migraine. J Neurol Sci 1993;114:109-116.

85. Van Woert MH, Rosenbaum D, Chung E. Fluoxetine in the treatment of intention myoclonus. Clinical Neuropharmacol 1983;1:49-54.

86. Van Woert MH, Rosenbaum D, Howieson J, Bowers MB Jr. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa. N Eng J Med1977:296:70-75.

87. Vanhoutte PM. Serotonin and the vascular wall. International J Cardiology 1987;14:189-203.

88. Warnock JK, Kestenbaum T. Pharamcologic treatment of severe skin-picking behaviors in Prader-Willi syndrome. Two case reports. Arch Dermatology 1992;128:1623-1625.

89. Weltzin TE, Fernstrom MH, Fernstrom JD, Neuberger SK, Kaye WH: Acute tryptophan depletion and increased food intake and irritability in bulimia nervosa. Am J Psychiatry 1995;152:1668-1671.

90. Young SN, Ervin FR, Pihl RO, Finn P. Biochemical aspects of tryptophan depletion in primates. Psychopharmacology 1989;98:508-511.

91. Young SN, Pihl RO, Ervin FR. The effect of altered tryptophan levels on mood and behavior in normal human males. Clin Neuropharmacol 1988;11: suppl 1:S207-S215.

Back to Chapter